[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606945":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":116,"collaborators":19,"id":118,"slug":119,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":19,"eligibilityCriteria":124,"healthyVolunteers":120,"sex":125,"minAge":126,"maxAge":19,"enrollmentInfo":127,"targetDuration":19,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":145,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},{"fullName":5,"class":6},"Normunity AccelCo, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NRM-823","EXPERIMENTAL","Administered per protocol requirements",[13],"Drug: NRM-823",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","NRM-823 is a bispecific T-Cell Engager",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Viviana Bozon, MD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Judy Schnyder, MBA","CONTACT","215-593-7119","judy.schnyder@normunity.com",[31,45,54,63,72,81,90,99,107],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":19},"Normunity Investigational Site","RECRUITING","Denver","Colorado","80220","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-104.9847,39.73915,{"lat":43,"lon":42},{"facility":32,"status":33,"city":46,"state":47,"zip":48,"country":37,"countryCode":38,"cosmosGeoPoint":49,"geoPoint":53,"contacts":19},"New Haven","Connecticut","06519",{"type":40,"coordinates":50},[51,52],-72.92816,41.30815,{"lat":52,"lon":51},{"facility":32,"status":33,"city":55,"state":56,"zip":57,"country":37,"countryCode":38,"cosmosGeoPoint":58,"geoPoint":62,"contacts":19},"Minneapolis","Minnesota","55425",{"type":40,"coordinates":59},[60,61],-93.26384,44.97997,{"lat":61,"lon":60},{"facility":32,"status":33,"city":64,"state":65,"zip":66,"country":37,"countryCode":38,"cosmosGeoPoint":67,"geoPoint":71,"contacts":19},"Maumee","Ohio","43537",{"type":40,"coordinates":68},[69,70],-83.65382,41.56283,{"lat":70,"lon":69},{"facility":32,"status":33,"city":73,"state":74,"zip":75,"country":37,"countryCode":38,"cosmosGeoPoint":76,"geoPoint":80,"contacts":19},"Philadelphia","Pennsylvania","19107",{"type":40,"coordinates":77},[78,79],-75.16362,39.95238,{"lat":79,"lon":78},{"facility":32,"status":33,"city":82,"state":83,"zip":84,"country":37,"countryCode":38,"cosmosGeoPoint":85,"geoPoint":89,"contacts":19},"Nashville","Tennessee","37203",{"type":40,"coordinates":86},[87,88],-86.78444,36.16589,{"lat":88,"lon":87},{"facility":32,"status":33,"city":91,"state":92,"zip":93,"country":37,"countryCode":38,"cosmosGeoPoint":94,"geoPoint":98,"contacts":19},"Dallas","Texas","75230",{"type":40,"coordinates":95},[96,97],-96.80667,32.78306,{"lat":97,"lon":96},{"facility":32,"status":33,"city":100,"state":92,"zip":101,"country":37,"countryCode":38,"cosmosGeoPoint":102,"geoPoint":106,"contacts":19},"San Antonio","78229",{"type":40,"coordinates":103},[104,105],-98.49363,29.42412,{"lat":105,"lon":104},{"facility":32,"status":33,"city":108,"state":109,"zip":110,"country":37,"countryCode":38,"cosmosGeoPoint":111,"geoPoint":115,"contacts":19},"Fairfax","Virginia","22031",{"type":40,"coordinates":112},[113,114],-77.30637,38.84622,{"lat":114,"lon":113},{"type":117,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100606945","phase-1-a-phase-1-study-of-nrm-823-in-participants-with-locally-advanced-or-metastatic-refractory-solid-tumors-100606945",false,"NCT07182149","A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors","A Phase 1a\u002F1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors","Inclusion Criteria:\n\n* Have histologically- or cytologically-diagnosed NSCLC (squamous or adenocarcinoma), TNBC, HNSCC, ESCC, esophageal adenocarcinoma, gastric\u002FGEJ adenocarcinoma, cervical, endometrial, or ovarian cancer which is advanced or metastatic.\n* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Adequate liver, renal, pulmonary, and cardiac function.\n* Adequate hematologic function.\n\nExclusion Criteria:\n\n* Has received cytotoxic chemotherapy, biologic anticancer agents, checkpoint inhibitors, or radiation therapy (excluding bone-only radiation therapy) ≤3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of NRM-823\n* History of Grade 2 pneumonitis requiring steroids or any Grade 3 or 4 pneumonitis from any prior therapy.\n* Has received an investigational therapy \\\u003C4 weeks or 5 half-lives prior to the first dose of NRM823, whichever is shorter prior to the first dose of NRM-823.\n* With the exception of alopecia and Grade ≤2 neuropathy, any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study drug.","ALL","18 Years",{"count":128,"type":129},150,"ESTIMATED","INTERVENTIONAL",[132],"PHASE1","This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.",[135,136,137,138,139,140,141,142,143,144],"HNSCC","ESCC","Esophageal Adenocarcinoma","Gastric Adenocarcinoma","GEJ Adenocarcinoma","Ovarian Cancer","NSCLC","Cervical Cancer","Endometrial Cancer","Triple Negative Breast Cancer (TNBC)",[9],"2026-02-10",{"date":148,"type":149},"2026-02-12","ACTUAL",{"date":151,"type":149},"2025-10-30",{"date":153,"type":129},"2028-10-31",{"name":5,"class":6},9]